In patients with acute kidney injury or in diseases like chronic obstructive pulmonary disease (COPD) which are based on the excessive CXCR2-driven recruitment of neutrophils [56], TRPC6 channel inhibition could represent a mild therapeutic approach with fewer side effects that improves patient outcome without completely downregulating the neutrophil function. The gene discussed is CXCR2; the disease is chronic obstructive pulmonary disease.